Lithuanian medical technology startup Sentante has achieved a major milestone: the company’s endovascular robotic platform has received CE Mark authorization for the European market. This certification indicates that the device has successfully met all stringent safety and efficacy regulations, officially transitioning from the research and development phase to commercialization. The deployment of this platform in hospitals and clinics across Europe is set to revolutionize the treatment of cardiovascular and neurovascular diseases.
What is the Sentante Robot?
The Sentante system is a device-agnostic, open platform, meaning it is compatible with standard catheters and guidewires already used in medicine.
Unlike traditional robotic surgical systems controlled via joysticks, Sentante utilizes innovative haptic feedback technology. From a dedicated control panel, the doctor performs the exact same movements they would make at the patient’s operating table, and the robot replicates them in real time. Crucially, the system transmits full tactile sensation and resistance force to the surgeon’s fingertips, providing a sense of safety and maximum control.
This technology seems familiar—why is it a turning point for medicine?
Endovascular surgeries, such as clot removal during a stroke or angioplasty, are highly time-dependent, critical procedures. During an ischemic stroke, approximately two million brain neurons die with every passing minute.
Current traditional practice faces three major challenges:
-
Geographical Inequality: The majority of highly skilled neurosurgeons work in large, specialized medical centers, meaning the transportation of regional patients often wastes precious time.
-
Radiation Exposure: Doctors spend hours standing under radiation while wearing heavy lead aprons, posing long-term health risks.
-
Physical Fatigue: Prolonged shifts lead to spinal and joint issues among surgeons.
Sentante’s innovative solution fully addresses these challenges. The robot is placed next to the patient’s bed in the operating room, while the surgeon operates from a completely radiation-safe, protected room, or even from another city or continent. Unlike its technological counterparts, it can operate using instruments, probes, or catheters of any size or brand, removing many commercial limitations currently faced by clinics.
Global Achievements and Plans for the US Market
Before receiving the CE Mark, Lithuanian-based Sentante passed several impressive historical milestones. In October 2025, a successful transatlantic cadaver surgery was conducted. Neurosurgeon Ricardo Hanel performed the procedure on a specialized anatomical model at the University of Dundee while controlling the robot from Florida, 4,000 miles away. Supported by Nvidia and Ericsson’s 5G technologies, the signal latency was just 120 milliseconds.
Later, in December 2025, 24 operations were performed on live animal models in Paris. The robot was controlled from three different locations in Europe and the US, and transferring control from one country to another took less than a minute.
Alongside international recognition, the company is actively establishing a foothold in the American market. The US Food and Drug Administration (FDA) granted the Sentante system “Breakthrough Device Designation” and included it in the special TAP program, which will significantly accelerate the start of human clinical trials and final licensing in the United States.
What’s Next?
Following the European authorization, Sentante’s management, led by CEO Edvardas Satkauskas, will shift its focus toward initial placements of the devices in European hospitals, physician training, and expanding the commercial network.
Concurrently, the company recently introduced its new product, the Digital Indeflator, which ensures precise pressure control during endovascular procedures (such as stenting) and will further complement their robotic ecosystem.
